Abstract
Treatment of differentiated thyroid cancer (DTC) most often involves a combination of surgery, radioactive iodine (RAI) and suppression of thyroid-stimulating hormone (TSH). In specific situations, external beam radiotherapy (EBRT) could be of benefit, although this remains controversial because of a lack of randomized evidence to support its use. In contrast, EBRT is of standard use in the multimodal management of anaplastic thyroid cancer (ATC) with surgery and systemic agents. Despite this, outcomes remain poor, supporting the need for additional research of this devastating disease. This chapter focuses on the role of EBRT in DTC and ATC.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call